Literature DB >> 12098631

Opioid receptors on white blood cells: effect of HIV infection and methadone treatment.

Martina Beck1, Alireza Mirmohammadsadegh, Barbara Franz, Jörg Blanke, Ulrich R Hengge.   

Abstract

Opioid receptors (OR) are involved in many physiological and pathological immune functions. During recent years, the treatment of opiate addiction with methadone in HIV-positive and HIV-negative patients has become widely accepted. However, little is known on the occurrence and course of OR on lymphocytes of these individuals. The objective of the study was to detect and quantify OR on peripheral white blood cells (WBC) by fluorescence-activated cell sorting using polyclonal antibodies and reverse transcriptase polymerase chain reaction, and to assess the influence of HIV infection and methadone treatment. We compared OR levels in 80 HIV-positive homosexuals, 18 HIV-positive intravenous drug users (IVDU) treated with methadone, 18 HIV-negative IVDU receiving methadone and 25 healthy controls. HIV infection was shown to decrease the amount of OR on WBC, especially of the delta-subtype on lymphocytes and granulocytes. The decrease correlated with the duration of HIV-infection (P<0.01), and inversely with the HIV viral load (P<0.01). In contrast, chronic methadone administration led to a significant increase of OR exclusively in HIV-negative IVDU. In particular the delta-OR was increased by 31-, 62- and 42-fold on lymphocytes, monocytes and granulocytes of HIV-negative patients (each P<0.005), respectively, which was not observed in HIV-positive IVDU. Therefore, HIV seems to reduce OR particularly on lymphocytes and granulocytes regardless of the mode of HIV transmission. The quantification of OR on immune cells may help to elucidate the effects of opioid analogues in health and drug addiction.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12098631     DOI: 10.1016/s0304-3959(02)00044-1

Source DB:  PubMed          Journal:  Pain        ISSN: 0304-3959            Impact factor:   6.961


  7 in total

1.  [Expression und function of the ORL-1 receptor on human leukocytes].

Authors:  C Krüger; L Köthe; A Struppert; C Pietruck; A Simm; S Grond
Journal:  Schmerz       Date:  2006-11       Impact factor: 1.107

Review 2.  Opioids, gliosis and central immunomodulation.

Authors:  Salim Kadhim; John McDonald; David G Lambert
Journal:  J Anesth       Date:  2018-07-27       Impact factor: 2.078

3.  Buprenorphine Increases HIV-1 Infection In Vitro but Does Not Reactivate HIV-1 from Latency.

Authors:  Germán Gustavo Gornalusse; Lucia N Vojtech; Claire N Levy; Sean M Hughes; Yeseul Kim; Rogelio Valdez; Urvashi Pandey; Christina Ochsenbauer; Rena Astronomo; Julie McElrath; Florian Hladik
Journal:  Viruses       Date:  2021-07-27       Impact factor: 5.818

4.  Expression of the mu opioid receptor in the human immunodeficiency virus type 1 transgenic rat model.

Authors:  Sulie L Chang; Jose A Beltran; Shilpa Swarup
Journal:  J Virol       Date:  2007-06-06       Impact factor: 5.103

Review 5.  Expression of Opioid Receptors in Cells of the Immune System.

Authors:  Jana Brejchova; Vladimir Holan; Petr Svoboda
Journal:  Int J Mol Sci       Date:  2020-12-30       Impact factor: 5.923

6.  Endogenous morphine levels are increased in sepsis: a partial implication of neutrophils.

Authors:  Elise Glattard; Ingeborg D Welters; Thomas Lavaux; Arnaud H Muller; Alexis Laux; Dan Zhang; Alexander R Schmidt; François Delalande; Benoît-Joseph Laventie; Sylvie Dirrig-Grosch; Didier A Colin; Alain Van Dorsselaer; Dominique Aunis; Marie-Hélène Metz-Boutigue; Francis Schneider; Yannick Goumon
Journal:  PLoS One       Date:  2010-01-20       Impact factor: 3.240

7.  Single cell transcriptomics reveals opioid usage evokes widespread suppression of antiviral gene program.

Authors:  Tanya T Karagiannis; John P Cleary; Busra Gok; Andrew J Henderson; Nicholas G Martin; Masanao Yajima; Elliot C Nelson; Christine S Cheng
Journal:  Nat Commun       Date:  2020-05-26       Impact factor: 17.694

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.